Acute Kidney Injury (AKI) and sepsis are major public health concerns, with high incidence, mortality and morbidity. Despite efforts to develop new interventions, current therapeutic options are limited in scope and effectiveness.
At Eliaz Therapeutics, we have developed a patented, unique medical device that will remove Galectin-3 (Gal-3) from human blood. Our device removes both bound and free Gal-3 from the circulation, offering a new treatment option that is less invasive and has fewer side-effects than other therapies.
The device promises to address a significant unmet need for effective interventions in the treatment of AKI and sepsis, in addition to other serious conditions.
Our Proof of Concept was a large animal study that showed how our medical device remarkably reduced inflammation and fibrosis. See the control and experimental photos below.
